Topic: 【ANN】【ICO】ClinTex CTi - Faster, Cheaper, Safer Medicine : DLT in Clinical Trials - page 4. (Read 5852 times)

I especially like point number 3 here. Most software used in the medical industry is archaic and data can routinely get corrupted, modified or lost. So ClinTex is offering a really valuable solution for just that problem alone.

It will run until the end of the tokensale so no set date as of now. Here's the bounty thread: https://bitcointalksearch.org/topic/rewards-campaign-clintex-blockchain-powered-clinical-trial-management-ended-4885007 

Hi there! Pharma companies running clinical trials will all initially agree to place clinical trial metrics and measures on blockchain to foster collaboration without risk of compromising commercial sensitivities and using the security and immutability of blockchain to protect data. So Clintex themselves won't be focussing on this initially, but the setup of the platform should minimize or remove the risk of these sensitivities. I hope this answers your question.

until when is the time for the bounty campaign?
is there a definite date?

Very good to know what you mentioned about the companies already they have partnered but one thing i want get clarification whether those companies will allow Clin Tex to use blockchain for their transaction in order get no fraud in between the mediators?

The Clintex CTi platform aims to drive cost efficiency by providing affordable clinical data analytics services.
Pharmaceutical companies gain deep insight into the operational and clinical aspects of their trials without the
necessity of major investment into backend technical infrastructure and data science expertise, whilst benefitting from the security of blockchain architecture.
The CTi platform distinguishes itself from other tools used in clinical trials by:

1. Bringing machine learning to clinical trial management;
2. Allowing for workflow management that “closes the loop”;
3. Enabling full audit-trail functionality to identify, action and resolve issues detected by the tool;
4. Eliminating the need for hardware costs to be borne by the client;
5. Introducing an attractive pay-per-use model for clients;
6. Applying powerful and insightful data analytics functionality across administrative, operational and clinical
functions in clinical trials;
7. Exploiting the immutability and interoperability of data filtered through the blockchain to create an
ecosystem that fosters collaboration across the entire pharmaceutical industry;
8. Being the first ever collaboration platform for clinical trials.

Don't forget to follow the team's subreddit here: https://www.reddit.com/r/clintexcti

Where you will find great content being shared like this interview with Neill Barron, Director of clinical data analytics

What inspired you to start building a collaboration platform for clinical trials for the pharmaceutical industry?

Simply put, pharma companies can learn from each other to develop and get medicines to patients faster. Realising the predictability of clinical trial issues, the question I asked myself was “How powerful would it be if one pharmaceutical company conducting a clinical trial could learn from another who has already conducted a clinical trial in the same disease area?”. Clintex CTi will allow that collaboration, whilst protecting commercial sensitivity. Very powerful predictive insights will be built up for use across the industry to more efficiently design and conduct clinical trials – learning from each other for the benefit of all.

If a company has huge potential they will not bother about  how much they raised because reputation and transparency will make them to reach their target. Efficiency will take time to prove but will succeed at last.

Is that from the whitepaper? Pretty great summary of how using a blockchain platform like Clintex brings big savings to the industry.

ClinTex CTi platform will be the first to bring a decentralised solution to the clinical trial  process, enabling pharmaceutical companies to maximise end-to-end efficiencies through the use of smart contracts, data sharing, operational and clinical visualisations, and predictive analytics using our decentralised applications.

There are 4 phases in the current clinical trials. In the first phase of a clinical trial, the proposed drug safety is tested  1/1 and those tests last for more than two months and usually involve a number of healthy volunteers who are paid to be
part of the trial. The aim of this study is to observe how would the human body react to the tested drug or device  and different dosages and intensity are included. The statistics showed the 70% of drugs/devices pass this phase.

The second phase tests the efficiency of the drug/device and usually lasts from several months to about two years.  The number of volunteers in this phase jumps to hundreds of people. Many of the studies conducted in this phase are  random and they are usually applied on two groups of people. The first group takes a dosage of the experimental  drug while the other group takes a standard medication while thinking that they're taking the actual experimental drug.  The researchers are unaware of the actual experiment too. This is done to observe the psychological effects and  human behavior. By gathering this information, the investigators deliver comparative information about the safety and  efficiency of the drug or device to pharmaceutical companies and the FDA. About 33.3% of the tested drugs or  devices go through phase I and II.

The third phase of clinical trials are randomized as well and they usually have several hundred to thousands of  volunteers. In this phase the scale of the testing is way bigger and testing a drug or device would take a minimum of  2 years or even more. By having a large number of volunteers, the investigators get a better understanding and more  details on the effectiveness, benefits, and the possible harmful or unwanted reactions. When a drug/device passes this  phase, pharmaceutical companies are able to request approval from the FDA to start marketing the drug.

The fourth phase and the last phase is named Post Marketing Surveillance Trial which is a study that starts after the  drug or the device is available for consumer use. There are three main objectives of this study, first pharmaceutical  companies compare the new drug or device to other existing drugs. Secondly, they observe the long-term effectiveness  of the drug on the patient's progress and life quality. Third, they determine the cost-effectiveness of the new drug  compared to existing or popular drugs. The results of this phase can lead to having the new drug or device taken off  the market, or some restrictions may apply when using the new medicine or tool.

The cost of running these clinical trials is now higher than ever, with expenses running at between $30 million and $70 million for a single Phase III trial.

Integrating Blockchain technology with Clinical trials will give the following benefits:

1: Security to the clinical data and protection from any alteration 

2: An immutable record that will show data and all changes in a consistent matter   

3: Past data that will show the complete history of clinical information

4: peer-2peer payments via smart contracts

5: Operation interoperability between several systems and data formats

6: Protection of privacy is possible. Blockchain technology allows adding and verifying records to an immutable ledger  without compromising the content of each record. 

7: Control of access to the content of each record by using encryption keys. The public key shows that the record  exists while the private key gives access to the content of the record.

Love the fact that they have a very detailed token allocation chart. Shows that the team is quite serious about how the funds are used to further the platform.

CLX Token Event Generation Details


Time: The TGE and TGE Pre-Sale is planned to commence in Q4, 2018. The exact dates are to be announced
CLX Base Price: USD $0.10c = 1 CLX
Hardcap: USD $17 million
Softcap: USD $4 million
Total Supply: 366,541,667 CLX tokens
Payment Method: BTC, ETH and BNB
Unsold tokens will get burnt

---------------------------------------------------

Here's the CLX token allocation

Public Sale: 35%
Pre-Sale: 15%
Strategic Partners Private Sale: 10%

Management Team: 10%
Shareholders: 10%
Team Incentive (Milestone Based Structured Bonus Scheme): 10%
Reserved for Advisors: 4%
Reserved for Referrals, Promotions & Bounty: 3%
Reserved for Pharma Industrial Trials (Testing): 3%

---------------------------------------------------

If you're interested in the ClinTex TGE, register your interest by signing up to the mailing list here:
https://www.clintex.io/token-generation-event/

If you have more questions, please drop them at the official ClinTex Telegram group
https://t.me/ClinTexCTi

The Ethereum Virtual Machine (EVM) is the software that runs on the Ethereum network and allows for the creation
and development of different applications all on one platform. It has an unparalleled track record in hosting
decentralised applications which enable the execution of smart contracts, which parties can fulfil certain conditions
and validate those conditions automatically using code. Due to smart contracts’ self-executing nature, single-party
manipulation is averted because control over the execution of the smart contract does not fall into the hands of a single party. Autonomy, trust, speed, and safety are Ethereum’s key strengths and these will be pivotal to the CTi ecosystem. While there are other DLT platforms in the space that promise a superior transaction speed per second, these promises have not yet been realised. Ethereum’s proven, viable and ready-to-use blockchain is the perfect platform on which to host the CTi eco-system.

It's already been posted!  It was a great interview, I think it's really reassuring that they're already planning on introducing the platform to UK sponsors that will be conducting local and global trials. It shows that they're not just in development, but also getting business deals done at the same time.

Check out Clintex recent interview with ICO-Alert
https://blog.icoalert.com/clintex-cti-ico-alert-report-851a45291e19

Share your thoughts below!

The main customers that ClinTex is aiming to offer the platform to large multinational pharmaceutical companies such as GlaxoSmithKline, Novartis, Pfizer, etc. The team is confident that the powerful product offering and favorable licensing propositions offered by ClinTex will drive rapid and widespread uptake of the CTi platform in the industry. 

Whether the company has any prediction about the market in the field of the medical sector. You will provide cheaper medicines to the customer but whether you have partnership with pharma companies and which countries you will firstly launching this type of specifications?

Hey guys, check out this interview with Neil & Brendan of ClinTex from ICO-Genius. They do a basic analysis of the project as well, it's well worth reading

https://blog.icoalert.com/clintex-cti-ico-alert-report-851a45291e19

ClinTex now have a litepaper too!

All key info without having to go through the whitepaper for your introduction to the future of safer, faster and cheaper Medicine!

https://clintex.io/Clintex_CTi_Litepaper.pdf

The ClinTex CTi platform will enable the delivery of inter-company collaboration across clinical trials through the creation of a clinical trial datahub populated from the key clinical trial source systems. Furthermore, advanced data analytics and machine learning will transform this datahub into insightful and actionable data to drive efficiency and quality in clinical research. The platform will be supported by 7 dApps